Oncotelic Initiates Clinical Trials Evaluating OT-101 against Pediatric Gliomas

(marketscreener.com) AGOURA HILLS, Calif., Nov. 08, 2022 -- Oncotelic Therapeutics, Inc , a developer of treatments for rare and orphan indications, including Parkinson’s Disease, PDAC, DIPG, and COVID-19, today announced that it has submitted a clinical study protocol to the US Food and Drug Administration for the initiation of a Phase 1 Trial for OT-101,...https://www.marketscreener.com/quote/stock/MATEON-THERAPEUTICS-INC-28722783/news/Oncotelic-Initiates-Clinical-Trials-Evaluating-OT-101-against-Pediatric-Gliomas-42240816/?utm_medium=RSS&utm_content=20221108